Evoke Pharma, Inc. (NASDAQ: EVOK) Stock Competitors & Peer Comparison

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, TAK has a market cap of 55.5B. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while TAK trades at $17.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas TAK's P/E ratio is 12.55. In terms of profitability, EVOK's ROE is -0.89%, compared to TAK's ROE of +0.02%. Regarding short-term risk, EVOK is less volatile compared to TAK. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check TAK's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, HLN has a market cap of 44.2B. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while HLN trades at $10.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas HLN's P/E ratio is 25.11. In terms of profitability, EVOK's ROE is -0.89%, compared to HLN's ROE of +0.17%. Regarding short-term risk, EVOK is less volatile compared to HLN. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check HLN's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, TEVA has a market cap of 41.2B. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while TEVA trades at $35.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas TEVA's P/E ratio is 12.06. In terms of profitability, EVOK's ROE is -0.89%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, EVOK is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check TEVA's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, VTRS has a market cap of 19.1B. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while VTRS trades at $16.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas VTRS's P/E ratio is 6.52. In terms of profitability, EVOK's ROE is -0.89%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, EVOK is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check VTRS's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while ITCI trades at $131.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas ITCI's P/E ratio is -180.64. In terms of profitability, EVOK's ROE is -0.89%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, EVOK is similarly volatile compared to ITCI. This indicates similar risk in terms of short-term price fluctuations for EVOK.Check ITCI's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while CTLT trades at $63.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas CTLT's P/E ratio is -27.84. In terms of profitability, EVOK's ROE is -0.89%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, EVOK is less volatile compared to CTLT. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check CTLT's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, ELAN has a market cap of 11B. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while ELAN trades at $22.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas ELAN's P/E ratio is 20.86. In terms of profitability, EVOK's ROE is -0.89%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, EVOK is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check ELAN's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, RDY has a market cap of 10.2B. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while RDY trades at $12.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas RDY's P/E ratio is 20.01. In terms of profitability, EVOK's ROE is -0.89%, compared to RDY's ROE of +0.09%. Regarding short-term risk, EVOK is less volatile compared to RDY. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check RDY's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while LNTH trades at $100.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas LNTH's P/E ratio is 16.97. In terms of profitability, EVOK's ROE is -0.89%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, EVOK is less volatile compared to LNTH. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check LNTH's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, AMRX has a market cap of 5.8B. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while AMRX trades at $18.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas AMRX's P/E ratio is 20.16. In terms of profitability, EVOK's ROE is -0.89%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, EVOK is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check AMRX's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, INDV has a market cap of 4.8B. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while INDV trades at $38.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas INDV's P/E ratio is 10.64. In terms of profitability, EVOK's ROE is -0.89%, compared to INDV's ROE of -2.16%. Regarding short-term risk, EVOK is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check INDV's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, SUPN has a market cap of 2.8B. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while SUPN trades at $47.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas SUPN's P/E ratio is 15.57. In terms of profitability, EVOK's ROE is -0.89%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, EVOK is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check SUPN's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, RGC has a market cap of 2.7B. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while RGC trades at $5.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas RGC's P/E ratio is -380.99. In terms of profitability, EVOK's ROE is -0.89%, compared to RGC's ROE of -2.32%. Regarding short-term risk, EVOK is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check RGC's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, BHC has a market cap of 2.3B. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while BHC trades at $6.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas BHC's P/E ratio is 1.59. In terms of profitability, EVOK's ROE is -0.89%, compared to BHC's ROE of +0.89%. Regarding short-term risk, EVOK is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check BHC's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while DCPH trades at $25.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas DCPH's P/E ratio is -11.58. In terms of profitability, EVOK's ROE is -0.89%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, EVOK is less volatile compared to DCPH. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check DCPH's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, HCM has a market cap of 2.2B. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while HCM trades at $12.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas HCM's P/E ratio is 4.69. In terms of profitability, EVOK's ROE is -0.89%, compared to HCM's ROE of +0.01%. Regarding short-term risk, EVOK is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check HCM's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while AVDL trades at $21.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, EVOK's ROE is -0.89%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, EVOK is similarly volatile compared to AVDL. This indicates similar risk in terms of short-term price fluctuations for EVOK.Check AVDL's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while EMBCV trades at $33.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas EMBCV's P/E ratio is N/A. In terms of profitability, EVOK's ROE is -0.89%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, EVOK is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check EMBCV's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while DVAX trades at $15.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas DVAX's P/E ratio is -41.89. In terms of profitability, EVOK's ROE is -0.89%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, EVOK is similarly volatile compared to DVAX. This indicates similar risk in terms of short-term price fluctuations for EVOK.Check DVAX's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, ANIP has a market cap of 1.8B. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while ANIP trades at $78.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas ANIP's P/E ratio is 9.52. In terms of profitability, EVOK's ROE is -0.89%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, EVOK is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check ANIP's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, PRGO has a market cap of 1.8B. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while PRGO trades at $12.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas PRGO's P/E ratio is 5.13. In terms of profitability, EVOK's ROE is -0.89%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, EVOK is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check PRGO's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while TARO trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas TARO's P/E ratio is 30.05. In terms of profitability, EVOK's ROE is -0.89%, compared to TARO's ROE of +0.03%. Regarding short-term risk, EVOK is less volatile compared to TARO. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check TARO's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while HROW trades at $40.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas HROW's P/E ratio is 449.33. In terms of profitability, EVOK's ROE is -0.89%, compared to HROW's ROE of -0.34%. Regarding short-term risk, EVOK is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check HROW's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while PAHC trades at $34.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas PAHC's P/E ratio is 11.70. In terms of profitability, EVOK's ROE is -0.89%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, EVOK is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check PAHC's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, ALVO has a market cap of 1.3B. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while ALVO trades at $3.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas ALVO's P/E ratio is -11.21. In terms of profitability, EVOK's ROE is -0.89%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, EVOK is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check ALVO's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, ETON has a market cap of 1.2B. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while ETON trades at $44.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas ETON's P/E ratio is -637.14. In terms of profitability, EVOK's ROE is -0.89%, compared to ETON's ROE of -0.06%. Regarding short-term risk, EVOK is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check ETON's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while CRON trades at $3.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas CRON's P/E ratio is 29.44. In terms of profitability, EVOK's ROE is -0.89%, compared to CRON's ROE of +0.06%. Regarding short-term risk, EVOK is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check CRON's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, PCRX has a market cap of 984.2M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while PCRX trades at $25.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas PCRX's P/E ratio is 9.62. In terms of profitability, EVOK's ROE is -0.89%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, EVOK is less volatile compared to PCRX. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check PCRX's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, COLL has a market cap of 955.8M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while COLL trades at $29.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas COLL's P/E ratio is 3.70. In terms of profitability, EVOK's ROE is -0.89%, compared to COLL's ROE of +0.16%. Regarding short-term risk, EVOK is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check COLL's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while PETQ trades at $30.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas PETQ's P/E ratio is 83.73. In terms of profitability, EVOK's ROE is -0.89%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, EVOK is less volatile compared to PETQ. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check PETQ's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, AMPH has a market cap of 916.3M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while AMPH trades at $20.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas AMPH's P/E ratio is 7.09. In terms of profitability, EVOK's ROE is -0.89%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, EVOK is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check AMPH's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, IRWD has a market cap of 711.1M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while IRWD trades at $4.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas IRWD's P/E ratio is 5.54. In terms of profitability, EVOK's ROE is -0.89%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, EVOK is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check IRWD's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, EVO has a market cap of 710.5M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while EVO trades at $2.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas EVO's P/E ratio is -2.82. In terms of profitability, EVOK's ROE is -0.89%, compared to EVO's ROE of -0.24%. Regarding short-term risk, EVOK is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check EVO's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while BDSI trades at $5.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas BDSI's P/E ratio is 6.82. In terms of profitability, EVOK's ROE is -0.89%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, EVOK is less volatile compared to BDSI. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check BDSI's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, TLRY has a market cap of 511.1M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while TLRY trades at $4.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas TLRY's P/E ratio is -7.21. In terms of profitability, EVOK's ROE is -0.89%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, EVOK is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check TLRY's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, EOLS has a market cap of 499.8M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while EOLS trades at $7.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas EOLS's P/E ratio is -24.04. In terms of profitability, EVOK's ROE is -0.89%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, EVOK is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check EOLS's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, AQST has a market cap of 494.3M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while AQST trades at $3.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas AQST's P/E ratio is -6.46. In terms of profitability, EVOK's ROE is -0.89%, compared to AQST's ROE of +1.91%. Regarding short-term risk, EVOK is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check AQST's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, KMDA has a market cap of 419.4M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while KMDA trades at $7.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas KMDA's P/E ratio is 20.77. In terms of profitability, EVOK's ROE is -0.89%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, EVOK is less volatile compared to KMDA. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check KMDA's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, CGC has a market cap of 409.5M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while CGC trades at $0.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas CGC's P/E ratio is -0.58. In terms of profitability, EVOK's ROE is -0.89%, compared to CGC's ROE of -0.31%. Regarding short-term risk, EVOK is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check CGC's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, TKNO has a market cap of 346.3M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while TKNO trades at $6.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas TKNO's P/E ratio is -20.84. In terms of profitability, EVOK's ROE is -0.89%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, EVOK is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check TKNO's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while ALIM trades at $5.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas ALIM's P/E ratio is 5.28. In terms of profitability, EVOK's ROE is -0.89%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, EVOK is less volatile compared to ALIM. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check ALIM's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while LNDC trades at $8.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas LNDC's P/E ratio is -4.04. In terms of profitability, EVOK's ROE is -0.89%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, EVOK is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check LNDC's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, EMBC has a market cap of 262.2M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while EMBC trades at $4.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas EMBC's P/E ratio is 1.70. In terms of profitability, EVOK's ROE is -0.89%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, EVOK is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check EMBC's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, ORGO has a market cap of 239.3M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while ORGO trades at $1.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas ORGO's P/E ratio is 62.00. In terms of profitability, EVOK's ROE is -0.89%, compared to ORGO's ROE of -0.27%. Regarding short-term risk, EVOK is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check ORGO's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while TYHT trades at $11.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas TYHT's P/E ratio is -1.61. In terms of profitability, EVOK's ROE is -0.89%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, EVOK is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check TYHT's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, SIGA has a market cap of 218.8M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while SIGA trades at $3.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas SIGA's P/E ratio is 11.30. In terms of profitability, EVOK's ROE is -0.89%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, EVOK is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check SIGA's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, LFCR has a market cap of 187.9M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while LFCR trades at $5.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas LFCR's P/E ratio is -4.68. In terms of profitability, EVOK's ROE is -0.89%, compared to LFCR's ROE of -1.95%. Regarding short-term risk, EVOK is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check LFCR's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, ACB has a market cap of 185.2M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while ACB trades at $2.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas ACB's P/E ratio is -6.10. In terms of profitability, EVOK's ROE is -0.89%, compared to ACB's ROE of -0.21%. Regarding short-term risk, EVOK is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check ACB's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while REPH trades at $2.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas REPH's P/E ratio is -8.04. In terms of profitability, EVOK's ROE is -0.89%, compared to REPH's ROE of -0.22%. Regarding short-term risk, EVOK is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check REPH's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, DERM has a market cap of 177M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while DERM trades at $6.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas DERM's P/E ratio is -17.38. In terms of profitability, EVOK's ROE is -0.89%, compared to DERM's ROE of -0.36%. Regarding short-term risk, EVOK is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check DERM's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, CRDL has a market cap of 163.7M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while CRDL trades at $1.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas CRDL's P/E ratio is -5.05. In terms of profitability, EVOK's ROE is -0.89%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, EVOK is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check CRDL's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while THTX trades at $3.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas THTX's P/E ratio is -28.83. In terms of profitability, EVOK's ROE is -0.89%, compared to THTX's ROE of +0.17%. Regarding short-term risk, EVOK is less volatile compared to THTX. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check THTX's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while ASRT trades at $23.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas ASRT's P/E ratio is -7.10. In terms of profitability, EVOK's ROE is -0.89%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, EVOK is less volatile compared to ASRT. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check ASRT's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, OGI has a market cap of 139.4M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while OGI trades at $0.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas OGI's P/E ratio is -3.81. In terms of profitability, EVOK's ROE is -0.89%, compared to OGI's ROE of -0.07%. Regarding short-term risk, EVOK is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check OGI's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, CPIX has a market cap of 116.9M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while CPIX trades at $7.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas CPIX's P/E ratio is -19.50. In terms of profitability, EVOK's ROE is -0.89%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, EVOK is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check CPIX's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while SCTL trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas SCTL's P/E ratio is -7.86. In terms of profitability, EVOK's ROE is -0.89%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, EVOK is less volatile compared to SCTL. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check SCTL's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while PROC trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas PROC's P/E ratio is 1.53. In terms of profitability, EVOK's ROE is -0.89%, compared to PROC's ROE of -2.22%. Regarding short-term risk, EVOK is similarly volatile compared to PROC. This indicates similar risk in terms of short-term price fluctuations for EVOK.Check PROC's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while OPTN trades at $9.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas OPTN's P/E ratio is -4.42. In terms of profitability, EVOK's ROE is -0.89%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, EVOK is similarly volatile compared to OPTN. This indicates similar risk in terms of short-term price fluctuations for EVOK.Check OPTN's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while ZOM trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas ZOM's P/E ratio is -1.62. In terms of profitability, EVOK's ROE is -0.89%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, EVOK is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check ZOM's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, ZYBT has a market cap of 89.6M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while ZYBT trades at $1.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas ZYBT's P/E ratio is -8.59. In terms of profitability, EVOK's ROE is -0.89%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, EVOK is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check ZYBT's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while GRVI trades at $4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas GRVI's P/E ratio is 26.05. In terms of profitability, EVOK's ROE is -0.89%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, EVOK is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check GRVI's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while ZYNE trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, EVOK's ROE is -0.89%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, EVOK is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check ZYNE's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while SSIC trades at $10.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas SSIC's P/E ratio is 11.93. In terms of profitability, EVOK's ROE is -0.89%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, EVOK is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check SSIC's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while VLNS trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas VLNS's P/E ratio is -1.03. In terms of profitability, EVOK's ROE is -0.89%, compared to VLNS's ROE of N/A. Regarding short-term risk, EVOK is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check VLNS's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, BGM has a market cap of 60.3M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while BGM trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas BGM's P/E ratio is -1.04. In terms of profitability, EVOK's ROE is -0.89%, compared to BGM's ROE of -0.07%. Regarding short-term risk, EVOK is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check BGM's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while DRRX trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas DRRX's P/E ratio is -4.44. In terms of profitability, EVOK's ROE is -0.89%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, EVOK is similarly volatile compared to DRRX. This indicates similar risk in terms of short-term price fluctuations for EVOK.Check DRRX's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, INCR has a market cap of 58M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while INCR trades at $0.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas INCR's P/E ratio is -2.26. In terms of profitability, EVOK's ROE is -0.89%, compared to INCR's ROE of -0.09%. Regarding short-term risk, EVOK is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check INCR's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while JUPW trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas JUPW's P/E ratio is -2.41. In terms of profitability, EVOK's ROE is -0.89%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, EVOK is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check JUPW's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while QLI trades at $5.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas QLI's P/E ratio is -4.92. In terms of profitability, EVOK's ROE is -0.89%, compared to QLI's ROE of -0.16%. Regarding short-term risk, EVOK is similarly volatile compared to QLI. This indicates similar risk in terms of short-term price fluctuations for EVOK.Check QLI's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while HEXO trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas HEXO's P/E ratio is -0.26. In terms of profitability, EVOK's ROE is -0.89%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, EVOK is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check HEXO's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, TLPH has a market cap of 29.3M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while TLPH trades at $1.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas TLPH's P/E ratio is -4.61. In terms of profitability, EVOK's ROE is -0.89%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, EVOK is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check TLPH's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, RMTI has a market cap of 28.5M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while RMTI trades at $7.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas RMTI's P/E ratio is -6.89. In terms of profitability, EVOK's ROE is -0.89%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, EVOK is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check RMTI's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, AYTU has a market cap of 25.3M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while AYTU trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas AYTU's P/E ratio is -1.23. In terms of profitability, EVOK's ROE is -0.89%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, EVOK is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check AYTU's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, TXMD has a market cap of 24M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while TXMD trades at $2.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas TXMD's P/E ratio is 105.45. In terms of profitability, EVOK's ROE is -0.89%, compared to TXMD's ROE of +0.01%. Regarding short-term risk, EVOK is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check TXMD's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while CYTH trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas CYTH's P/E ratio is -0.80. In terms of profitability, EVOK's ROE is -0.89%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, EVOK is similarly volatile compared to CYTH. This indicates similar risk in terms of short-term price fluctuations for EVOK.Check CYTH's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, BFRIW has a market cap of 17M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while BFRIW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas BFRIW's P/E ratio is -0.03. In terms of profitability, EVOK's ROE is -0.89%, compared to BFRIW's ROE of -4.77%. Regarding short-term risk, EVOK is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check BFRIW's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, OPTH has a market cap of 16.3M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while OPTH trades at $5.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas OPTH's P/E ratio is -18.56. In terms of profitability, EVOK's ROE is -0.89%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, EVOK is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check OPTH's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while ACRX trades at $0.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas ACRX's P/E ratio is -0.31. In terms of profitability, EVOK's ROE is -0.89%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, EVOK is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check ACRX's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, COSM has a market cap of 12.7M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while COSM trades at $0.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas COSM's P/E ratio is -0.38. In terms of profitability, EVOK's ROE is -0.89%, compared to COSM's ROE of -0.96%. Regarding short-term risk, EVOK is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check COSM's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while AGRX trades at $1.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas AGRX's P/E ratio is -0.89. In terms of profitability, EVOK's ROE is -0.89%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, EVOK is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check AGRX's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while NLTX trades at $3.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas NLTX's P/E ratio is -0.28. In terms of profitability, EVOK's ROE is -0.89%, compared to NLTX's ROE of -0.38%. Regarding short-term risk, EVOK is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check NLTX's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while LCI trades at $0.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas LCI's P/E ratio is -0.04. In terms of profitability, EVOK's ROE is -0.89%, compared to LCI's ROE of +1.66%. Regarding short-term risk, EVOK is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check LCI's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while ADMP trades at $0.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas ADMP's P/E ratio is -0.08. In terms of profitability, EVOK's ROE is -0.89%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, EVOK is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check ADMP's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, YCBD has a market cap of 5.9M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while YCBD trades at $0.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas YCBD's P/E ratio is -1.38. In terms of profitability, EVOK's ROE is -0.89%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, EVOK is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check YCBD's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, GELS has a market cap of 5M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while GELS trades at $0.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas GELS's P/E ratio is -1.09. In terms of profitability, EVOK's ROE is -0.89%, compared to GELS's ROE of -0.25%. Regarding short-term risk, EVOK is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check GELS's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while MNK trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas MNK's P/E ratio is -0.44. In terms of profitability, EVOK's ROE is -0.89%, compared to MNK's ROE of -0.26%. Regarding short-term risk, EVOK is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check MNK's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while FLGC trades at $7.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas FLGC's P/E ratio is -0.19. In terms of profitability, EVOK's ROE is -0.89%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, EVOK is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check FLGC's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, CPHI has a market cap of 3.6M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while CPHI trades at $1.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas CPHI's P/E ratio is -1.76. In terms of profitability, EVOK's ROE is -0.89%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, EVOK is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check CPHI's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, UPC has a market cap of 3.5M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while UPC trades at $5.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas UPC's P/E ratio is -0.69. In terms of profitability, EVOK's ROE is -0.89%, compared to UPC's ROE of -0.03%. Regarding short-term risk, EVOK is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check UPC's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, SBFM has a market cap of 2.9M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while SBFM trades at $1.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas SBFM's P/E ratio is -0.20. In terms of profitability, EVOK's ROE is -0.89%, compared to SBFM's ROE of -0.26%. Regarding short-term risk, EVOK is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check SBFM's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, SHPH has a market cap of 2.6M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while SHPH trades at $4.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas SHPH's P/E ratio is -0.20. In terms of profitability, EVOK's ROE is -0.89%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, EVOK is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check SHPH's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while PLXP trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas PLXP's P/E ratio is -0.22. In terms of profitability, EVOK's ROE is -0.89%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, EVOK is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check PLXP's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, SNOA has a market cap of 2.4M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while SNOA trades at $1.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas SNOA's P/E ratio is -1.22. In terms of profitability, EVOK's ROE is -0.89%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, EVOK is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check SNOA's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while ATNX trades at $0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas ATNX's P/E ratio is -0.02. In terms of profitability, EVOK's ROE is -0.89%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, EVOK is similarly volatile compared to ATNX. This indicates similar risk in terms of short-term price fluctuations for EVOK.Check ATNX's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while PROCW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas PROCW's P/E ratio is N/A. In terms of profitability, EVOK's ROE is -0.89%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, EVOK is similarly volatile compared to PROCW. This indicates similar risk in terms of short-term price fluctuations for EVOK.Check PROCW's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, RDHL has a market cap of 1.9M. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while RDHL trades at $0.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas RDHL's P/E ratio is 0.12. In terms of profitability, EVOK's ROE is -0.89%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, EVOK is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check RDHL's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, YCBD-PA has a market cap of 928.2K. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while YCBD-PA trades at $1.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas YCBD-PA's P/E ratio is -2.69. In terms of profitability, EVOK's ROE is -0.89%, compared to YCBD-PA's ROE of -0.34%. Regarding short-term risk, EVOK is less volatile compared to YCBD-PA. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check YCBD-PA's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, CYTHW has a market cap of 928K. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while CYTHW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas CYTHW's P/E ratio is N/A. In terms of profitability, EVOK's ROE is -0.89%, compared to CYTHW's ROE of -7.30%. Regarding short-term risk, EVOK is similarly volatile compared to CYTHW. This indicates similar risk in terms of short-term price fluctuations for EVOK.Check CYTHW's competition here

Evoke Pharma, Inc. (NASDAQ: EVOK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOK stands at 18.9M. In comparison, LSDI has a market cap of 906.9K. Regarding current trading prices, EVOK is priced at $11.00 on the NASDAQ, while LSDI trades at $0.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOK currently has a P/E ratio of -7.97, whereas LSDI's P/E ratio is -0.07. In terms of profitability, EVOK's ROE is -0.89%, compared to LSDI's ROE of +181.47%. Regarding short-term risk, EVOK is less volatile compared to LSDI. This indicates lower risk in terms of short-term price fluctuations for EVOK.Check LSDI's competition here